首页 | 本学科首页   官方微博 | 高级检索  
检索        

鼻渊通窍颗粒联合莫西沙星治疗急性鼻窦炎的临床研究
引用本文:吴泽幼,包思,梁敬,许俊藩.鼻渊通窍颗粒联合莫西沙星治疗急性鼻窦炎的临床研究[J].现代药物与临床,2017,32(4):657-660.
作者姓名:吴泽幼  包思  梁敬  许俊藩
作者单位:1. 南方医科大学南方医院药剂科,广东广州,510515;2. 南方医科大学南方医院耳鼻喉科,广东广州,510515
摘    要:目的探讨鼻渊通窍颗粒联合莫西沙星治疗急性鼻窦炎的临床疗效。方法选取2015年10月—2016年10月在南方医科大学南方医院接收治疗的急性鼻窦炎患者150例,随机分为对照组(75例)和治疗组(75例)。对照组患者口服盐酸莫西沙星片,1片/次,1次/d。治疗组在对照组的基础上口服鼻渊通窍颗粒,1袋/次,3次/d。两组患者均治疗14 d。比较两组患者临床疗效、临床症状评分和血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为81.33%、96.00%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,两组患者鼻塞、鼻涕和头痛评分均较治疗前明显降低,同组比较差异具有统计学意义(P0.05);且治疗组比对照组降低更显著,两组比较差异具有统计学意义(P0.05)。与治疗前相比,治疗后两组患者血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平明显降低,而IL-10水平明显升高,同组比较差异具有统计学意义(P0.05);且治疗组上述血清炎性因子水平改善更明显,两组比较差异具有统计学意义(P0.05)。结论鼻渊通窍颗粒联合莫西沙星治疗急性鼻窦炎的临床效果显著,可明显改善患者临床症状和降低血清炎性因子,具有一定的临床推广应用价值。

关 键 词:鼻渊通窍颗粒  盐酸莫西沙星片  急性鼻窦炎  血清炎性因子  超敏C反应蛋白
收稿时间:2016/12/29 0:00:00

Clinical study on Biyuan Tongqiao Granules combined with moxifloxacin in treatment of acute sinusitis
WU Ze-you,BAO Si,LIANG Jing and XU Jun-fan.Clinical study on Biyuan Tongqiao Granules combined with moxifloxacin in treatment of acute sinusitis[J].Drugs & Clinic,2017,32(4):657-660.
Authors:WU Ze-you  BAO Si  LIANG Jing and XU Jun-fan
Institution:Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China;Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China;Department of Pharmacy, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China;Department of ENT, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China
Abstract:Objective To evaluate the clinical efficacy of Biyuan Tongqiao Granules combined with moxifloxacin in treatment of acute sinusitis.Methods Patients (150 cases) with acute sinusitis in Nanfang Hospital of Southern Medical University from October 2015 to October 2016 were randomly divided into control (75 cases) and treatment (75 cases) groups. Patients in the control group werepo administered withMoxifloxacin Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were poadministered with Biyuan Tongqiao Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy, clinical symptom scores, and serum inflammatory factors in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 81.33% and 96.00% respectively, and there was difference between two groups (P < 0.05). After treatment, the nasal congestion, runny nose, and headache scores in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Compared with those before treatment, the hs-CRP, IL-6, and TNF-α levels in two groups significantly decreased, but the IL-10 level significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these serum inflammatory factors levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Biyuan Tongqiao Granules combined with moxifloxacin has significant clinical effect in treatment of acute sinusitis, can significantly improve the clinical symptoms and reduce the serum inflammatory factors, which has a certain clinical application value.
Keywords:Biyuan Tongqiao Granules  Moxifloxacin Hydrochloride Tablets  acute sinusitis  serum inflammatory factor  hs-CRP
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号